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Factors regulating differentiation of the peripheral nervous system (PNS) have been widely studied in neuroblastomas which are tumors of the 
PNS. Five neuroblastomas were investigated for their content of tachykinin neuropeptides, which arise from two distinct genes which appear differ- 
entially expressed in the PNS. Radioimmunoassay and column chromatography revealed large amounts of neurokinin B in three of these tumors 
and the absence of substance P, neurokinin A, neuropeptide K and neuropeptide y from all five tumors. This suggests that neuroblastomas can 
selectively express the preprotachykinin (PPT) II gene and that they may be valuable for investigating the factors involved in the regulation of 
these two structurally-related neuropeptide genes. 
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1. INTRODUCTION 
The mammalian tachykinin family of neuropeptides 
are derived from two distinct genes. Four tachykinin 
peptides, substance P, neurokinin A and the neurokinin 
A-derived, neuropeptide K and neuropeptide y, arise 
from the preprotachykinin (PPT) I gene [l-3] whereas 
neurokinin B is the only tachykinin deriving from the 
PPT II gene [4,5]. Substance P has been the most exten- 
sively studied of these peptides and has a widespread 
distribution in the central and peripheral nervous 
systems (CNS and PNS) [6]. This undecapeptide is an 
invariable product of PPT I gene expression. However, 
PPT I gene expression also involves cell-specific dif- 
ferential post-transcriptional (alternative mRNA splic- 
ing) and post-translational (alternative ndoproteolysis) 
processing [7], which affect the tissue concentrations of 
neurokinin A and its amino-terminally extended eriva- 
tives neuropeptides K and y, relative to those of sub- 
stance P [7-91. Similar heterogeneity in the expression 
of the PPT II gene is not evident. Neurokinin B appears 
to have a distinctly different distribution to that of 
substance P and neurokinin A. In the CNS in situ hybri- 
disation studies of PPT I and PPT II mRNAs indicate 
that, besides at least one example of colocalisation of 
these mRNAs [lo], they are mostly expressed in quite 
separate sets of neurons [l 11. Also this differential ex- 
pression of PPT I and II genes would seem to occur in 
the PNS. Thus substance P and neurokinin A are found 
in many peripheral organs, predominantly within nerve 
terminals of C-fibre afferent neurons [ 12,131 whose cell 
bodies are in the cranial and dorsal root sensory ganglia 
and contain large amounts of PPT I mRNA [ 11,141 but 
no PPT II mRNA [ll]. 
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Peripheral sympathetic neurons of the rat have also 
been shown to express the PPT I gene and have been the 
focus of studies by Black and coworkers, investigating 
the regulatory factors which influence PPT I gene ex- 
pression [ 15,161. There is no evidence that the neurons 
express the PPT II gene. Neuroblastomas are neo- 
plasms of the peripheral nervous system which appear 
to be derived from progenitive neuroblasts of sympa- 
thetic neurons. They are of potential value in investi- 
gations of the mechanisms of peripheral neuronal 
development and differentiation [17]. The aim of this 
study was to characterise which tachykinins are present 
in these tumors. Radioimmunoassays for the tachy- 
kinins have been combined with analytical column 
chromatographic methods including reverse-phase (rp) 
HPLC capable of resolving the different mammalian 
tachykinins. 
Abbreviations: PNS, peripheral nervous system; CNS, central ner- 
vous system; PPT, preprotachykinin; NKA-IR, neurokinin A- 
immunoreactivity; SP-IR, substance P-IR; rpHPLC, reverse-phase 
high-pressure liquid chromatography; K., affinity constant; IDso con- 
centration giving 50% inhibition 
2. MATERIALS AND METHODS 
2.1. Materials 
Peptides were obtained from either Peninsula Labs, St. Helens, UK 
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or Bachem Biochemica GmbH, Heidelberg, Germany. ‘Iodogen’ 
reagent (I ,3,4,6-tetrachloro-3a,ba-diphenyl glycouril) was obtained 
from Pierce, Heidelberg, Germany. rpHPLC cartridges and solvents 
were obtained from Merck, Darmstadt, Germany. Sepak C,s car- 
tridges were obtained from Waters Associates, Milford, USA. 
Sephadex GXI (fine) for gel permeation chromatography was obtained 
from Pharmacia Uppsala, Sweden. 
2.2. Tissues and extraction method 
Specimens from 5 freshly diagnosed abdominal neuroblastomas 
were obtained during surgery and kept frozen at -80°C until in- 
vestigation. Diagnosis was based on clinical signs, elevated circulating 
catecholamines and their metabolites as well as on histopathology. 
For comparison with normal peripheral tissues, human specimens of 
duodenum and colon removed at surgery for different reasons and 
taken for the purpose of routine histology and found to be normal, 
were used. The peptide contents of the tumor and intestinal tissues 
were extracted in boiling 0.5 M acetic acid [lS]. 20 ml of each of the 
extract solutions were partially purified by adsorption onto a Sepak 
cartridge of octadecylsilica s previously described in detail [19]. The 
eluted fractions were evaporated in a vacuum centrifuge (Speed Vat) 
to between 100 and 200~1. Complete drying of samples was avoided 
to maximise recovery of peptide. Samples were then diluted to 2 ml 
with 0.1% TFA and then stored at -80°C until assay and 
chromatographic analysis. 
2.3. Radioimmunoassays (RIAs) 
The substance P RIA was that previously described [18] except hat 
the radiolabelled tracer was prepared similarly as described below for 
the neurokinin RIA. The RIA employs the rabbit antiserum SP3 
which exhibits less than 0.1% crossreaction with neurokinins A and 
B and neuropeptide K and neuropeptide y. The neurokinin RIA 
employed a rabbit antiserum raised to neurokinin A coupled by 
glutaraldehyde to bovine serum albumin (BSA). The antiserum ~$4 
was selected because of its high affinity (& = 2.4 & 0.3 x 10” l/mol) 
and its significant crossreaction with neurokinin B, neuropeptides K
and y and not with substance P (see Results). The tracer was 
radiolabelled ‘ZS1-tyr-O-NKA prepared using the Iodogen reagent, 
followed by purification on rpHPLC. 
2.4, rpHPLC 
For rpHPLC analysis, 1 ml of the partially-purified tissue extracts 
was diluted in 1 ml 50 mM potassium phosphate buffer, pH 2.5 (sol- 
vent A), and centrifuged (10000 x g) to remove insoluble debris. Each 
sample was injected onto a 125 x 4 mm LiChro CART column of Cle 
LiChrospher (IOO-RP-18,.5pm), preequilibrated with solvent A. After 
sample injection the column was eluted with a linear gradient of sol- 
vent B (acetonitrile/water (70: 30) containing potassium phosphate 
buffer, final concentration 37 mM, pH 2.5). The exact gradient condi- 
tions used are indicated in Fig. 2. Each of the fractions was 
evaporated to 50-100~1 ina vacuum centrifuge, followed by addition 
of 1 ml RIA buffer and then assayed at dilution for tachykinin- 
immunoreactivity. The column was calibrated with picomole quan- 
tities of standard synthetic tachykinins and elution times were deter- 
mined by RIA. In this way possible contamination of the injector, 
which was also thoroughly washed between runs, and column was 
minimised. 
2.5. Gel permeation chromatography 
2 ml of each of the partially purified tissue extracts were loaded on- 
to a 90x 1.6 cm column of GSO Sephadex (fine), eluted with 40 mM 
potassium phosphate buffer, pH 7.4, containing 150 mM sodium 
chloride, 0.2% BSA and 0.25% sodium azide. The flow rate was 30 
ml/h and 4 min (2 ml) fractions were collected and assayed at dilu- 
tion. The void and total volumes of the column bed were determined 
from the elution time of Dextran blue (Pharmacia) and NaI (contain- 
ing a trace amount of NalZSI), respectively. The elution time of the 
different tachykinins was determined under identical conditions and 
was detected by RIA. 
3. RESULTS AND DISCUSSION 
Table I shows the sequence homology shared by 
neurokinin A, neurokinin B, neuropeptide K and 
neuropeptide y. The latter two contain the complete 
neurokinin A sequence at the carboxy-terminus and are 
derived, respectively, from preprotachykinins ,6 and y 
which both arise from the PPT I gene by way of alter- 
native mRNA splicing [7]. Neurokinin B shares with 
neurokinin A the complete carboxy-terminal amidated 
pentapeptide sequence. The polycional antibody used in 
this study, ~$4, is clearly directed to this sequence since 
it exhibits significant crossreaction with all these 
homologous peptides (Fig. 1). Taking the IDso values 
for inhibition of binding of ‘251-Tyr-O-neurokinin A to 
polyclonal antibody, ~$4, for each of these four pep- 
tides and dividing them into the value obtained for 
neurokinin A, allows a quantitative estimate of 
crossreactivity. The assay shows full crossreaction with 
neuropeptide K (loo%), reduced crossreaction with 
neurokinin B (30%) and, unexpectedly, the polyclonal 
antibody appears to have greater affinity for neuropep- 
tide y (180%) than for neurokinin A. The differing 
amino-terminal sequences of neurokinin B and neuro- 
peptide y must confer some conformational change in 
and/or steric influence on the carboxy-terminal se- 
quence in order to affect the immunoreactivity in op- 
posing ways. 
Table II shows that high concentrations of neuro- 
kinin A-immunoreactivity (NKA-IR) were measured in 
3 of the 5 neuroblastomas but that there was no detec- 
table substance P-immunoreactivity (SP-IR). This is a 
novel observation in view of the widely reported paral- 
le1 distribution of neurokinin A and substance P in 
peripheral organs (7-91. In Table III this is illustrated 
by the similar concentrations of NKA-IR and SP-IR 
measured in extracts of normal human intestine; 
Table 1 
Primary sequences of neurokinin A and related peptides with extent of carboxy-terminal 
sequence homology outlined 
neurokinin A 
neuropeptide K
neuropeptide y
neurokinin B 
84 
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Fig. 1. Displacement of binding (% B/B,) of ‘251-Tyr-O-neurokinin A 
to polyclonal antibody ~$4 by increasing concentrations of 
neurokinin A (x), neurokinin B (e), neuropeptide K (A), neuropep- 
tide y (0) and substance P (a). 
rpHPLC, under optimised conditions, could resolve the 
various tachykinins (Fig. 2). The NKA-IR of each of 
the three NKA-IR positive tumor extracts elutes as one 
major peak coeluting with the neurokinin B standard. 
The profile for two of the tumors is shown in Fig. 2. 
Treatment of synthetic neurokinin B, which contains 
two methionine residues, with hydrogen peroxide under 
conditions known to convert methionine-containing 
peptides to their sulphoxide form ]20] was found to 
generate two earlier eluting peaks (arrows 4 and 5 in 
Fig. 2) The neuroblastoma NKA-IR presented on 
rpHPLC a significant peak of immunoreactivity with 
the elution time of one of these presumed oxidised 
forms of neurokinin B. None of the neurobolastoma 
NKA-IR eluted in the position of neurokinin A, neuro- 
peptide K or neuropeptid~ y. In contrast, the NKA-IR 
of an extract of human colon appears more hetero- 
geneous on rpHPLC and peaks of immunoreactivity 
were resolved with elution times corresponding to the 
various tachykinin standards and some of their oxidised 
forms. A similar profile was obtained for an extract of 
human duodenum (data not shown). In these human in- 
testinal extracts the major peak of immunor~activit~ 
corresponds to neurokinin A. 
Table II 
Co~~ntra~~ons (pmoflg wet weight) of ~~rok~n~~ A (NKA)- and 
substance P fSP)-like ~mmunoreact~vities in individuaf sampies of 
human neuroblastoma nd intestine 
NKA SP 
Neuroblastoma 
I 
2 
3 
4 
5 
Duodenum 
Colon 
32 CO.5 
400 CO.5 
<0.5 <OS 
160 <0.5 
<0*5 <OS 
43 39 
38 41 
= 
E 
60 
Tumor 4 
1.5 
1.0 
0.5 
0 
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Time (min) 
Fig. 2. Profiles of NKA-IR of extracts of two neuroblastoma tumors 
(2 and 4) and one human coton, fractionated on an rpHPLC column. 
The cofumn was duted with a linear gradient of increasing concentra- 
tion of acetonitrile in the eluting solvent. Arrows indicate dution- 
times of oxidised neurakinin A (11, neuropeptide y (2). neurokinin A 
(31, oxidised neurokinin B (4+ 5), neuropeptide K (6) and neurokinin 
B (7). 
The identity of the neuroblastoma NKA-IR as 
~eurokinin B was further supported by the gel permea- 
tion analysis. Neurokinin B, despite its very similar 
molecular weight to neurokinin A, elutes from the Gso 
Sephadex column with a peak elution volume signi- 
ficantly greater than that of neurokinin A (Fig. 3). This 
probably resuhs from the peptide’s particularly 
hydrophobic properties, resulting in some adsorption to 
the Sephadex which retards elutian. The neurobiastoma 
NKA-IR elutes with a peak elution volume correspon- 
ding to that of the neurokinin B standard. For com- 
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Fig. 3. Profile of NKA-IR fractionated on a C&O Sephadex of syn- 
thetic neurokinin A and B standards and of extracts of one 
neuroblastoma tumor (number 4) and a human colon. Arrows in- 
dicate calibrated elution positions of void (V,) and total (L’J volumes, 
synthetic neuropeptide K (1) neuropeptide y (2). neurokinin A (3) 
and neurokinin B (4). 
parison, in Fig. 3 is shown the elution profile of NKA- 
IR of a human colonic extract, which reveals one major 
peak of immunoreactivity with a peak elution volume 
corresponding to that of NKA. A discrete peak of 
NKA-IR was also found in the elution position cor- 
responding to neuropeptide K. The relatively low quan- 
tities of neuropeptide y and neurokinin B compared to 
neurokinin A which were resolved on rpHPLC of the 
identical extract are probably obscured on elution from 
the G~c, Sephadex column by the large neurokinin A 
component. 
Taking into account the reduced crossreaction of 
neurokinin B in the RIA employed here, significant 
amounts of the peptide appear to be present in the 
human intestine, albeit at about 10% of the concentra- 
tion of neurokinin A. This is an important observation 
in light of a recent report, using a neurokinin B-specific 
RIA demonstrating the absence of the neuropeptide 
from rodent intestine [21]. Neurokinin B has been 
postulated as the endogenous ligand of the pharmaco- 
logically-defined neurokinin-3 receptor which appears 
to mediate tachykinin effects on mammalian enteric 
neurons [22]. 
Whether neurokinin B in humans is produced by 
mature sympathetic neurons needs to be determined. 
Perhaps neurokinin B in neuroblastomas represents a 
transient expression of the PPT II gene during differen- 
tiation of sympathetic neurons or it is being produced 
ectopically. In the ontogenetically related adrenal 
medulla, PPT II mRNA has been detected in the ox [4]. 
Also in one human phaeochromocytoma, a tumor of 
the adrenal medulla, neurokinin B was detected using a 
neurokinin B-specific RIA, but at concentrations much 
lower than the neuroblastoma concentrations reported 
here [23]. In this same study, Kage and Conlon detected 
neurokinin B in only one of a series of 10 phaeochro- 
mocytomas and, interestingly, it was also the only one 
of the series in which products of the PPT I gene were 
detected. However, there was no histochemical assess- 
ment of whether cellular co-localisation of PPT I and II 
gene products occurs in this tumor. 
Evidence has been obtained here for the production 
by some neuroblastomas of neurokinin B but neither 
neurokinin A nor substance P which strongly suggests 
that the PPT II gene and not the PPT I gene is being 
selectively expressed. In normal tissues these genes ap- 
pear often to be seperately expressed which indicates 
that they are regulated by different control mecha- 
nisms. Similarly in carcinoid tumors, which are also 
neuroendocrine neoplasms, substance P and neurokinin 
A and its derivatives are frequently produced but not 
neurokinin B [20]. Perhaps further studies comparing 
neuroblastoma nd carcinoid tumor cells may reveal the 
factors which are involved in differential expression of 
the tachykinin genes. Furthermore neuroblastoma 
tissue could be a valuable source of PPT II mRNA and 
so facilitate cloning of cDNA and elucidation of the 
structure of the human neurokinin B precursor protein 
and also of the gene, So far only the rat and bovine 
neurokinin B precursor cDNAs and the corresponding 
bovine gene have been cloned and sequenced. The 
neuroblastomas investigated here did not differ with 
respect to their histological grading. The high expres- 
sion of neurokinin B in 3 of the 5, however, suggests 
that differences at the molecular level, which may 
become important for diagnosis and subclassification 
of the disease, do in fact exist. 
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